 
About the Program
Program Overview
This CME activity will feature four HCV experts reviewing and discussing the most important studies presented on chronic hepatitis C at AASLD. This review and discussion will provide unique insight into how knowledgeable experts review the key posters and presentations at AASLD and an in-depth understanding of the scientific quality and clinical relevance of the posters and presentations reviewed.
This program will enable all participating clinicians and health care providers caring for HCV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care.
Back to Top
Target Audience
This activity is intended for physicians, physician assistants, advanced practice nurses, and other health care professionals involved in the treatment and management of patients with HCV infection.
Back to Top
Learning Objectives
After completing this activity, participants should be able to:
-
Review clinically relevant posters and presentations on chronic hepatitis C made at the 62nd AASLD;
-
Explain to colleagues the clinical trials and data presented in the most important posters and presentations on chronic hepatitis C at the 62nd AASLD;
-
Discuss the scientific integrity and clinical relevance of the most important posters and presentations on chronic hepatitis C at the 62nd AASLD;
-
Use the information and data presented in the most important posters and presentations at the 62nd AASLD to improve patient care.
Release Date: November 17, 2011
Expiration Date: November 17, 2012
Estimated time to complete each Poster/Presentation: 15 minutes
Media: Internet
Back to Top
Faculty
Douglas T. Dieterich, MD
Professor of Medicine and Director of CME,
Department of Medicine,
Director of Outpatient Hepatology,
Division of Liver Diseases,
Mount Sinai School of Medicine
New York, New York
Paul Y. Kwo, MD
Associate Professor of Medicine
Medical Director, Liver Transplantation
Division of Gastroenterology and Hepatology
Indiana University School of Medicine
Indianapolis, Indiana
Jürgen Rockstroh, MD
Professor
University of Bonn
Bonn, Germany
Paul J. Pockros, MD
Head, Division of Gastroenterology/Hepatology
Director, SC Liver Research Consortium
The Scripps Clinic
La Jolla, California
Back to Top
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Postgraduate Institute for Medicine and ViralEd, Inc.. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Back to Top
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)TM per poster presentation. Physicians should claim only the credit commensurate with the extent of their participation in the activity
Disclosure of Conflicts of Interest
The Postgraduate Institute for Medicine requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by the Postgraduate Institute for Medicine for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Dr. Douglas Dieterich:
- Consulting Fees: Gilead; Merck; Boehringer Ingelheim; Indenix; Pharmasset; Vertex
Dr. Paul Kwo:
- Contracted Research: Anadys; Conatus; Merck; Roche; BMS; Gilead; Vertex; Abbott
- Consulting Fees: Merck; Vertex; Abbott; BMS; Gilead; Novartis; Boehringer Ingelheim; Johnson & Johnson
- Speakers' Bureau: Merck; Roche; BMS; Gilead
Dr. Paul Pockros:
- Contracted Research: Merck Genentech; Vertex; Janssen; Gilead; BMS; Conatus; Boehringer Ingelheim
- Consulting Fees: Merck; Conatus; Novartis; Boehringer Ingelheim; Vertex; Genentech; Janssen; BMS; Gilead
- Spakers' Bureau: Vertex; Genentech; BMS
Dr. Jurgen Rockstroh:
- Contracted Research: Abbott; Merck; Roche
- Consulting Fees: Abbott; BMS; Boehringer Ingelheim; Gilead; GSK; Merck; Pfizer; Roche; Tibotec; ViiV; Novartis; Bionor
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
The following planners and managers, Jan Hixon, RN, BSN, MA; Trace Hutchison, PharmD; Julia Kimball, RN, BSN; Samantha Mattiucci, PharmD; Jan Schultz, RN, MSN, CCMEP and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Back to Top
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Postgraduate Institute for Medicine, ViralEd, Inc. and Merck & Co. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Postgraduate Institute for Medicine, ViralEd, Inc. and Merck & Co. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Poster/Presentation Listing
|
1.
|
 |
TPV + PR and BOC + PR in HCV/HIV Co-infected Patients
|
|
2.
|
|
BMS-790052- Phase 2b A1444040 Study Interim Week 12 Results
|
|
3.
|
|
ENABLE 1 Study - Final Results
|
|
4.
|
|
The PROTON and ELECTRON Studies
|
|
5.
|
|
Protease Inhibitors with PegIFN/RBV: PILLAR, SILEN-C3, SILEN-C1 and ATLAS
|
|
6.
|
|
Dual Oral Combination Therapy with Daclatasvir and Asunaprevir
|
|
7.
|
|
Final Results of the SYNCH Multicenter Study
|
|
8.
|
|
Retreatment with TVR + PR After a Short Exposure to TVR in Phase 1
Studies: Interim Results from a Phase IIIb Rollover Trial (C219)
|
|
9.
|
|
Predictors of SVR Among Poor Interferon Responders When BOC is Added to PR and PROVIDE Study
|
|
10.
|
|
The Cost-Effectiveness of a Telaprevir-Inclusive Regimen as Initial Therapy for Genotype 1 Hepatitis C Infection in Individuals with the CC IL28B Polymorphism
|
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Supported by an educational grant from Merck & Co., Inc.
This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings
|
